Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center

Calapkulu, Murat; CANDER, SONER; ÖZ GÜL, ÖZEN; ERSOY, CANAN

doi:10.1016/j.dsx.2018.09.005

Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center

Atıf İçin Kopyala

Calapkulu M., CANDER S., ÖZ GÜL Ö., ERSOY C.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, cilt.13, sa.1, ss.284-288, 2019 (ESCI)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 13 Sayı: 1
Basım Tarihi: 2019
Doi Numarası: 10.1016/j.dsx.2018.09.005
Dergi Adı: DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
Sayfa Sayıları: ss.284-288
Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Introduction: Dapagliflozin is an antidiabetic drug that has been used as a member of the new antidiabetic drug group that acts by inhibiting SGLT-2 and increasing urinary glucose excretion. With numerous controlled experimental studies of dapagliflozin, evaluation of real-life data after entry into clinical practice is an important condition. In our study, the effects of dapagliflozin on glycemic control and anthropometric measurements were investigated retrospectively.